If you purchased BioTelemetry, Inc. securities and would like to join the action, please click "Join This Action" below.
BIOTELEMETRY MERGER INVESTIGATION: HALPER SADEH LLP ANNOUNCES INVESTIGATION INTO WHETHER THE SALE OF BIOTELEMETRY, INC. IS FAIR TO SHAREHOLDERS; INVESTORS ARE ENCOURAGED TO CONTACT THE FIRM – BEAT
December 18, 2020.
New York, New York—Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of BioTelemetry, Inc. (NASDAQ: BEAT) to Royal Philips for $72.00 per share in cash is fair to BioTelemetry shareholders.
The investigation concerns whether BioTelemetry and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to: (1) obtain the best possible price for BioTelemetry shareholders; (2) determine whether Royal Philips is underpaying for BioTelemetry; and (3) disclose all material information necessary for BioTelemetry shareholders to adequately assess and value the merger consideration. On behalf of BioTelemetry shareholders, Halper Sadeh LLP may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.
Halper Sadeh LLP represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.